(Moderna) Moderna Inc. has announced that the currently authorized 50 µg booster dose increased neutralizing antibodies against the Omicron by about 37 times. The 100-µg dose raised the neutralizing antibodies by up to 83 times.
Moderna CEO Stéphane Bancel says the results of the booster dose are reassuring at a time the world is experiencing heightened cases of the Omicron.
Bancel has promised to continue advancing Omicron-specific booster doses, including clinical testing if it becomes necessary. He also expects to continue sharing data with the authorities for informed decisions on vaccination strategies.
Moderna’s data incorporated 20 mRNA-1273 booster recipients each at the 50 µg and 100 µg dose levels.
MRNA: NASDAQ is up +5.97% on premarket.
